Skip to main content
HeartCited

NMN (Nicotinamide Mononucleotide) ： Heart Failure

D

Preclinical data shows NAD+ restoration may support cardiac function in animal heart failure models. No human heart failure trials yet. Mechanism through SIRT1 activation and mitochondrial biogenesis.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dnmn\u0026condition\u003Dheart\u002Dfailure'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            D

        

        

            
結論

            
            
Preclinical data shows NAD+ restoration may support cardiac function in animal heart failure models. No human heart failure trials yet. Mechanism through SIRT1 activation and mitochondrial biogenesis.

            
            
        

    











    
    

        
        

            

  
Key Statistics





            


    

        
0

        
研究数

    

    

        
--

        
参加者数

    

    

        
            
            ↑
            
        
        
Positive

    

    

        D

        
グレード

    




        


        
        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
一般的な使用量

                

                    
                    

                        
general:

                        
250-500 mg/day

                    

                    
                    

                        
antiagingprotocols:

                        
500-1,000 mg/day

                    

                    
                

                
                

                    上限量： Not formally established; up to 1,200 mg/day used in human trials without significant adverse e
                

                
            

            

            

            
            

                推奨摂取タイミング： Morning on empty stomach or with light meal; sublingual for enhanced bioavailability
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
報告されている副作用

                    
    
                        
                        
  • 
                            ⚠
                            Generally well-tolerated
                        
    • 
                        
                        
  • 
                            ⚠
                            Mild gastrointestinal discomfort
                        
    • 
                        
                        
  • 
                            ⚠
                            Flushing (rare)
                        
    • 
                        
                        
  • 
                            ⚠
                            Headache (rare)
                        
    • 
                        
                    

                

                

                
                

                    
既知の相互作用

                    
    
                        
                        
  • 
                            ●
                            May interact with NAD+-dependent medications
                        
    • 
                        
                        
  • 
                            ●
                            Theoretical interaction with diabetes medications (may affect glucose metabolism)
                        
    • 
                        
                    

                

                

                
                

                    

                        耐容上限摂取量： Not formally established; up to 1,200 mg/day used in human trials without significant adverse e
                    

                

                
            

            

                サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does NMN (Nicotinamide Mononucleotide) help with Heart Failure?
            
        
        

            Based on 0 studies with 0 participants, there is preliminary evidence that needs more research that NMN (Nicotinamide Mononucleotide) may support Heart Failure management. Our evidence grade is D (Very Early Research).
        

    

    
    

        
            How much NMN (Nicotinamide Mononucleotide) should I take for Heart Failure?
            
        
        

            Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of NMN (Nicotinamide Mononucleotide)?
            
        
        

            Reported side effects may include Generally well-tolerated, Mild gastrointestinal discomfort, Flushing (rare), Headache (rare). Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for NMN (Nicotinamide Mononucleotide) and Heart Failure?
            
        
        

            We rate the evidence as Grade D (Very Early Research). This rating is based on 0 peer-reviewed studies with 0 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                
                

                
                

                    
NMN (Nicotinamide Mononucleotide) 他の症状・状態について

                    

                        
                        
                            Arterial Stiffness
                            C

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDAに関する免責事項:
        これらの記述は米国食品医薬品局（FDA）による評価を受けていません。本ウェブサイトの製品および情報は、疾病の診断、治療、治癒、または予防を目的としたものではありません。表示されているエビデンスグレードは、公開された査読済み研究の分析に基づいており、医療上の助言を構成するものではありません。サプリメントの摂取を開始する前に、必ず医療専門家にご相談ください。